SOURCE: Stock Market Alerts

October 17, 2007 09:10 ET

Breaking Stock Alert for Wednesday: POSC! October 17, 2007

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Stock Market Alerts.

MIAMI, FL--(Marketwire - October 17, 2007) - Stock Market Alerts' performance stock list includes: Positron Corporation (OTCBB: POSC), General Electric Company (NYSE: GE), Pfizer Inc. (NYSE: PFE), Johnson & Johnson (NYSE: JNJ).

Targeting the multi-billion dollar medical imaging industry, Positron Corporation (OTCBB: POSC) should have investors monitoring the stock closely! Yesterday after the markets closed, the company, which designs, manufactures, markets and supports advanced cardiac molecular imaging devices utilizing single photon emission computed tomography (SPECT) and positron emission tomography (PET), issued a press release announcing that it displayed their PULSE CDC™ SPECT imaging system, as well as introduced their new dedicated Cardiac PET system that is expected to receive 510k FDA approval in spring 2008, at the Annual meeting of The American Society of Nuclear Cardiology.

This is good news for POSC, as the meeting attendees consisted of more than 1,500 nuclear cardiologists, practice administrators and technologists with the majority operating myocardial perfusion imaging with private cardiology practices. Market research from the ASNC meeting suggested that the cardiologist market would readily move to compliment their molecular imaging offering by adding Positron's cost effective Attrius system especially due to the proposed cardiac PET reimbursement increase (Jan 1, 2008).

Continue to watch this company! According to the press release, Positron is expecting significant demand for their product since they will be the only vendor offering an all new PET only molecular imaging system for less than $600,000 with the primary focus on cardiology. Positron intends to be the first company to offer absolute coronary flow reserve calculations developed by K. Lance Gould, M.D. Dr. Gould is considered the founder of Cardiac PET combined with the discovery of flow reserve in human studies.

Positron Corporation's President, Joseph Oliverio stated, "The American Society of Nuclear Cardiology meeting confirmed our internal market research. We strongly believe that we are in a great position to be the leader in the rapidly expanding market of Cardiac PET. We will be the only company that is focused on bringing to market an affordable dedicated cardiac PET scanner with superior technology and disease focused software. We anticipate receiving our 510k FDA approval in spring of 2008."

The company's stock closed at Six cents a share

Positron Corporation designs, manufactures, markets and supports advanced cardiac molecular imaging devices utilizing single photon emission computed tomography (SPECT) and positron emission tomography (PET). The company's molecular imaging systems incorporate patented and proprietary software and hardware technology for the diagnosis and treatment of patients with heart disease. Positron Corporation offers unique combination of low cost technology and disease specific software solutions differentiating themselves from all other medical device manufacturers.

Other Stocks of interest yesterday were:

General Electric Company (NYSE: GE) down 0.1% on 35.2 million shares traded. GE, a diversified technology, media and financial services company focused on solving some of the world's toughest problems. With products and services ranging from aircraft engines, power generation, water processing and security technology to medical imaging, business and consumer financing, media content and advanced materials, GE serves customers in more than 100 countries and employs more than 300,000 people worldwide.

Pfizer Inc. (NYSE: PFE) down 1.4% on 44.5 million shares traded. Pfizer is committed to helping people improve their health by discovering and developing medicines, as well as informing consumers and health care providers about our medicines and the medical conditions they treat. Through multiple initiatives, Pfizer aims to enhance access to treatments and educate, empower and motivate consumers to take the necessary steps to lead longer, healthier, happier lives.

Johnson & Johnson (NYSE: JNJ) down 0.8% on 14.3 million shares traded. Johnson & Johnson is a manufacturer of health care products.

The advertisement is provided by Wall Street Enews, a division of Stock Market Alerts LLC, an electronic broadcaster and publisher of this release, and hereafter referred to as "the company." The company received compensation for services performed for Positron Corporation (OTCBB: POSC). The compensation was fourteen thousand dollars, from third party, GDB Media Inc., who may hold a significant position in the stock. Because the company received compensation for its services, there is an inherent conflict of interest in the company statements and opinions and such statements and opinions cannot be considered independent.

The information contained in this press release is for informational purposes only, and not to be construed as an offer to sell or solicitation of an offer to buy any security. The company makes no representation or warranty relating to the validity of the facts presented nor does the company represent or warrant that all material facts necessary to make an investment decision are presented above. Stock Market Alerts LLC is an advertising company and therefore, this release should be viewed for informational purposes only.

The company relies exclusively on information gathered on the public company, such as public filings, press releases and its web sites. Investors should use the advertising information contained in this release as a starting point for conducting additional research on the public company in order to allow the investor to form his or her own opinion regarding the public company. Factual statements contained in this publication are made as of the date stated and they are subject to change without notice. The company is not a registered investment adviser, broker or a dealer.

Investing in the public company that this release is providing service for should be reviewed as speculative and a high-risk and may result in the loss of some or all of any investment.

This release may contain statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements.

Contact Information